Nomination of a novel plasma protein biomarker panel capable of classifying Alzheimer's disease dementia with high accuracy in an African American cohort
Kuchenbecker, L. A.; Thompson, K. J.; Hurst, C. D.; Opdenbosch, B. M.; Heckman, M. G.; Reddy, J. S.; Nguyen, T.; Casellas, H. L.; Reddy, D. J.; Lucas, J. A.; Day, G. S.; Willis, F. B.; Graff-Radford, N. R.; Ertekin-Taner, N.; Kalari, K. R.; Carrasquillo, M. M.
Show abstract
IntroductionAfrican Americans (AA) are widely underrepresented in plasma biomarker studies for Alzheimers disease (AD) and current diagnostic biomarker candidates do not reflect the heterogeneity of AD. MethodsUntargeted proteome measurements were obtained using the SomaScan 7k platform to identify novel plasma biomarkers for AD in a cohort of AA clinically diagnosed as AD dementia (n=183) or cognitively unimpaired (CU, n=145). Machine learning approaches were implemented to identify the set of plasma proteins that yields the best classification accuracy. ResultsA plasma protein panel achieved an area under the curve (AUC) of 0.91 to classify AD dementia vs CU. The reproducibility of this finding was observed in the ANMerge plasma and AMP-AD Diversity brain datasets (AUC=0.83; AUC=0.94). DiscussionThis study demonstrates the potential of biomarker discovery through untargeted plasma proteomics and machine learning approaches. Our findings also highlight the potential importance of the matrisome and cerebrovascular dysfunction in AD pathophysiology.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Deciphering cellular transcriptional alterations in Alzheimer's disease brains 96%
- Interrogating the plasma proteome of repetitive head impact exposure and chronic traumatic encephalopathy 96%
- Large-scale CSF proteome profiling identifies biomarkers for accurate diagnosis of Frontotemporal Dementia 96%
Similar papers in this journal
- An interim exploratory biomarker analysis of a Phase 2 clinical trial to assess the impact of CT1812 in Alzheimers disease 97%
- Retinal tau phosphorylation in Alzheimer's disease: a mass spectrometry study 95%
- Regional interneuron transcriptional changes reveal pathologic markers of disease progression in a mouse model of Alzheimer's disease 95%
Similar papers in this journal
- Genetic and Multi-omic Risk Assessment of Alzheimer’s Disease Implicates Core Associated Biological Domains 94%
- A metabolite-based machine learning approach to diagnose Alzheimer's-type dementia in blood: Results from the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort 94%
- Relationship between therapeutic activity and preferential targeting of toxic soluble aggregates by amyloid-beta-directed antibodies 93%
Similar papers in this journal
- A Temporal Quantitative Profiling of Newly Synthesized Proteins during Aβ Accumulation 96%
- Therapeutic Targeting of Casein Kinase 1δ/ε in an Alzheimer's Disease Mouse Model 92%
- Enrichment of neurodegenerative microglia signature in brain-derived extracellular vesicles isolated from Alzheimer's disease mouse model 92%